Search results
Results from the WOW.Com Content Network
On December 17, 2009, Rev. Bryan A. Krumm, CNP, filed a rescheduling petition for Cannabis with the DEA arguing that "because marijuana does not have the abuse potential for placement in Schedule I of the CSA, and because marijuana now has accepted medical use in 13 states, and because the DEA's own Administrative Law Judge has already ...
If the U.S. Drug Enforcement Administration reclassified marijuana as a less dangerous drug, it wouldn't eliminate the conflicts between the feds and states such as California that have legalized ...
The President made descheduling and other cannabis reforms a topic of the 2024 State of the Union Address; [2] it was the first time the word "marijuana" had been used in a State of the Union Address since Ronald Reagan called it a target of the War on Drugs alongside cocaine in 1988. [3]
Yet one organizer, who helped unsuccessful petition efforts in 2022 and 2023, hopes federal reclassification of marijuana nudges more lawmakers to support legalization.
The Biden administration plans to reclassify marijuana for the first time since the Controlled Substances Act was enacted more than 50 years ago. DEA to reclassify marijuana, easing restrictions ...
The year 2023 began with several state efforts to legalize adult-use or medical cannabis, despite an apparently stalled federal effort to do so. [1] A cannabis industry executive predicted that at least two states would enact adult-use reform in 2023, with the most likely states to legalize being Minnesota, Pennsylvania and Ohio. [2]
No changes are expected to the medical marijuana programs now licensed in 38 states or the legal recreational cannabis markets in 23 states, but it's unlikely they would meet the federal production, record-keeping, prescribing and other requirements for Schedule III drugs.
Schedule III drugs are easier to study, though the reclassification wouldn't immediately reverse all barriers to study. “It’s going to be really confusing for a long time,” said Ziva Cooper, director of the University of California, Los Angeles Center for Cannabis and Cannabinoids.